ES3001145T1 - Conjugados que comprenden un fosforo (v) y un resto de camptotecina - Google Patents

Conjugados que comprenden un fosforo (v) y un resto de camptotecina Download PDF

Info

Publication number
ES3001145T1
ES3001145T1 ES22817180T ES22817180T ES3001145T1 ES 3001145 T1 ES3001145 T1 ES 3001145T1 ES 22817180 T ES22817180 T ES 22817180T ES 22817180 T ES22817180 T ES 22817180T ES 3001145 T1 ES3001145 T1 ES 3001145T1
Authority
ES
Spain
Prior art keywords
optionally substituted
conjugate according
residue
alkyl
substituted aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES22817180T
Other languages
English (en)
Spanish (es)
Inventor
Marc-André Kasper
Paul Machui
Isabelle Mai
Annette Vogl
Saskia Schmitt
Dominik Schumacher
Jonas Helma-Smets
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tubulis GmbH
Original Assignee
Tubulis GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tubulis GmbH filed Critical Tubulis GmbH
Publication of ES3001145T1 publication Critical patent/ES3001145T1/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES22817180T 2021-11-09 2022-11-09 Conjugados que comprenden un fosforo (v) y un resto de camptotecina Pending ES3001145T1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21207284 2021-11-09
PCT/EP2022/081371 WO2023083919A1 (en) 2021-11-09 2022-11-09 Conjugates comprising a phosphorus (v) and a camptothecin moiety

Publications (1)

Publication Number Publication Date
ES3001145T1 true ES3001145T1 (es) 2025-03-04

Family

ID=78592674

Family Applications (1)

Application Number Title Priority Date Filing Date
ES22817180T Pending ES3001145T1 (es) 2021-11-09 2022-11-09 Conjugados que comprenden un fosforo (v) y un resto de camptotecina

Country Status (16)

Country Link
US (1) US20230158154A1 (enExample)
EP (1) EP4429709A1 (enExample)
JP (1) JP2024540692A (enExample)
KR (1) KR20240100415A (enExample)
CN (1) CN118302198A (enExample)
AU (1) AU2022386680A1 (enExample)
CA (1) CA3237379A1 (enExample)
CL (1) CL2024001373A1 (enExample)
CO (1) CO2024005880A2 (enExample)
DE (1) DE22817180T1 (enExample)
ES (1) ES3001145T1 (enExample)
IL (1) IL312677A (enExample)
MX (1) MX2024005545A (enExample)
PE (1) PE20242114A1 (enExample)
TW (1) TW202339803A (enExample)
WO (1) WO2023083919A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
AU2024332412A1 (en) 2023-09-01 2026-03-12 Tubulis Gmbh Methods of preparing phosphonamidate compounds
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US12521446B2 (en) 2024-02-27 2026-01-13 Bristol-Myers Squibb Company Anti-CEACAM5 antibody drug conjugates
WO2025262641A1 (en) 2024-06-19 2025-12-26 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
WO2026016639A1 (zh) * 2024-07-19 2026-01-22 昆山新蕴达生物科技有限公司 一种靶向adam-9的抗体-药物偶联物及其制备方法和用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
JP3008226B2 (ja) 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
JP2763020B2 (ja) 1995-04-27 1998-06-11 日本電気株式会社 半導体パッケージ及び半導体装置
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
EP0964702B1 (en) 1996-08-02 2006-10-04 Ortho-McNeil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
SV2007002227A (es) 2004-09-10 2007-03-20 Wyeth Corp Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637
US7687496B2 (en) * 2007-10-16 2010-03-30 Bionumerik Pharmaceuticals, Inc. C7-substituted camptothecin analogs
NZ610239A (en) 2008-04-30 2014-11-28 Immunogen Inc Cross-linkers and their uses
ES3029483T3 (en) * 2008-09-17 2025-06-24 Endocyte Inc Folate receptor binding conjugates of antifolates
NZ758049A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
JP7137474B2 (ja) 2016-03-15 2022-09-14 メルサナ セラピューティクス，インコーポレイティド ＮａＰｉ２ｂ標的化抗体－薬物コンジュゲート及びその使用方法
AU2017320913B2 (en) 2016-09-01 2024-08-15 Forschungsverbund Berlin E.V. Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates
KR102772724B1 (ko) 2018-03-07 2025-02-24 포슝스베르분드 베를린 에.베. 알켄 또는 알킨-포스포노티올레이트 및 -포스포네이트로의 화학선택적 티올-접합
BR112020020466A2 (pt) * 2018-04-06 2021-01-12 Seattle Genetics, Inc. Conjugados de peptídeo de camptotecina
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
EP3976112A1 (en) 2019-06-03 2022-04-06 Synaffix B.V. Acetal-based cleavable linkers
IL289094A (en) * 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for increasing the speed and yield of the "click release" reaction
DK3983363T3 (da) * 2019-06-17 2024-06-24 Tagworks Pharmaceuticals B V Forbindelser til hurtig og effektiv klikfrigivelse

Also Published As

Publication number Publication date
CO2024005880A2 (es) 2024-07-08
DE22817180T1 (de) 2024-12-12
US20230158154A1 (en) 2023-05-25
PE20242114A1 (es) 2024-10-28
EP4429709A1 (en) 2024-09-18
JP2024540692A (ja) 2024-10-31
KR20240100415A (ko) 2024-07-01
IL312677A (en) 2024-07-01
CL2024001373A1 (es) 2024-10-25
TW202339803A (zh) 2023-10-16
CA3237379A1 (en) 2023-05-19
CN118302198A (zh) 2024-07-05
AU2022386680A1 (en) 2024-06-20
WO2023083919A1 (en) 2023-05-19
MX2024005545A (es) 2024-07-19

Similar Documents

Publication Publication Date Title
ES3001145T1 (es) Conjugados que comprenden un fosforo (v) y un resto de camptotecina
AU2020263231B2 (en) Camptothecin derivatives
EP4410372A1 (en) Antibody, antibody-drug conjugate thereof and use thereof
ES2999335T1 (en) Conjugates comprising a phosphorus (v) and a drug moiety
CN108883198B (zh) 基于艾日布林的抗体-药物偶联物和使用方法
CA2026147C (en) Cytotoxic agents comprising maytansinoids and their therapeutic use
JP2024540692A5 (enExample)
JP2018502047A (ja) 生物学的物質及びその使用
IL303707A (en) Camptothecin antibody-drug conjugates and methods of using them
KR20150085808A (ko) 약물 단백질 결합체
MX2009002855A (es) Profarmacos polimericos dirigidos que contienen enlazadores multifuncionales.
TW202408589A (zh) 抗ror1抗體及抗體結合物、包含抗ror1抗體或抗體結合物之組合物，及製造及使用抗ror1抗體及抗體結合物之方法
JP7706668B2 (ja) 抗体－薬物コンジュゲート及びそれらの使用
WO2024235136A9 (zh) 杂环类化合物及其制备方法和用途
CN116847885A (zh) 用于抗体-药物缀合物的双切割酯接头
AU2023221765B2 (en) Masked il12 protein
WO2024235130A9 (zh) 多环化合物及其制备方法和用途
WO2024235133A9 (zh) 多环类药物偶联物及其制备方法和用途
WO2026046180A1 (en) Compounds, conjugates and uses thereof
CA3237677C (en) Epsilon-poly-l-lysine-based drug conjugate, intermediate thereof, and application thereof
WO2024235135A1 (zh) 大环化合物及其制备方法和用途
WO2024235131A1 (zh) 大环类药物偶联物及其制备方法和用途
WO2025064424A9 (en) Tandem-cleavage linkers for antibody-drug conjugates and uses thereof
CN120923577A (zh) 大环类药物偶联物及其制备方法和用途
WO2024083926A1 (en) Novel antibody drug conjugates with novel napi2b antibodies, therapeutic methods and uses thereof